Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Protein kinase signaling networks in cancer.

Brognard J, Hunter T.

Curr Opin Genet Dev. 2011 Feb;21(1):4-11. doi: 10.1016/j.gde.2010.10.012. Epub 2010 Nov 29. Review.

2.

Challenges and opportunities in defining the essential cancer kinome.

Manning BD.

Sci Signal. 2009 Mar 24;2(63):pe15. doi: 10.1126/scisignal.263pe15. Review.

PMID:
19318621
3.

Protein kinases curb cell death.

Filhol O, Cochet C.

Sci Signal. 2011 May 10;4(172):pe26. doi: 10.1126/scisignal.2001921.

PMID:
21558553
4.

The mutational landscape of phosphorylation signaling in cancer.

Reimand J, Wagih O, Bader GD.

Sci Rep. 2013 Oct 2;3:2651. doi: 10.1038/srep02651.

5.

Reconfiguring phosphorylation signaling by genetic polymorphisms affects cancer susceptibility.

Wang Y, Cheng H, Pan Z, Ren J, Liu Z, Xue Y.

J Mol Cell Biol. 2015 Jun;7(3):187-202. doi: 10.1093/jmcb/mjv013. Epub 2015 Feb 26.

PMID:
25722345
6.

Mammalian TOR signaling to the AGC kinases.

Su B, Jacinto E.

Crit Rev Biochem Mol Biol. 2011 Dec;46(6):527-47. doi: 10.3109/10409238.2011.618113. Epub 2011 Oct 10. Review.

7.

Oncogenes are to lose control on signaling following mutation: should we aim off target?

Hornberg JJ, Westerhoff HV.

Mol Biotechnol. 2006 Oct;34(2):109-16.

PMID:
17172656
8.

Phosphoproteomics for oncology discovery and treatment.

Stern DF.

Expert Opin Ther Targets. 2005 Aug;9(4):851-60. Review.

PMID:
16083347
9.

Modeling Signaling Networks to Advance New Cancer Therapies.

Saez-Rodriguez J, MacNamara A, Cook S.

Annu Rev Biomed Eng. 2015;17:143-63. doi: 10.1146/annurev-bioeng-071813-104927. Epub 2015 Aug 14. Review.

PMID:
26274601
10.

Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation.

Trusolino L, Bertotti A.

Cancer Discov. 2012 Oct;2(10):876-80. doi: 10.1158/2159-8290.CD-12-0400.

11.

Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers.

Reimand J, Bader GD.

Mol Syst Biol. 2013;9:637. doi: 10.1038/msb.2012.68.

12.

Targeting the mTOR signaling network in cancer.

Chiang GG, Abraham RT.

Trends Mol Med. 2007 Oct;13(10):433-42. Epub 2007 Oct 1. Review.

PMID:
17905659
13.

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.

Gallo LH, Nelson KN, Meyer AN, Donoghue DJ.

Cytokine Growth Factor Rev. 2015 Aug;26(4):425-49. doi: 10.1016/j.cytogfr.2015.03.003. Epub 2015 Apr 20. Review.

16.

Receptor proximal kinases in NF-κB signaling as potential therapeutic targets in cancer and inflammation.

Verstrepen L, Beyaert R.

Biochem Pharmacol. 2014 Dec 15;92(4):519-29. doi: 10.1016/j.bcp.2014.10.017. Epub 2014 Nov 7. Review.

PMID:
25449604
17.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
18.

Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

Memmott RM, Dennis PA.

Cell Signal. 2009 May;21(5):656-64. doi: 10.1016/j.cellsig.2009.01.004. Epub 2009 Jan 7. Review.

19.

Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis.

Kang NJ, Shin SH, Lee HJ, Lee KW.

Pharmacol Ther. 2011 Jun;130(3):310-24. doi: 10.1016/j.pharmthera.2011.02.004. Epub 2011 Feb 26. Review.

PMID:
21356239
20.

The phosphoinositide 3-kinase pathway.

Cantley LC.

Science. 2002 May 31;296(5573):1655-7. Review.

PMID:
12040186

Supplemental Content

Support Center